Jang Hee Hong
Overview
Explore the profile of Jang Hee Hong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
257
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Song J, Koh H, Moon H, Jung J, Hong J, Sunwoo J
Medicine (Baltimore)
. 2024 Nov;
103(46):e40494.
PMID: 39560548
Background: Osteoarthritis (OA) is a prevalent joint disease affecting the spine, hands, hips, knees, and feet. However, definitive drugs for OA are lacking, and current treatments are limited owing to...
2.
Kim D, Hong J, Jung W, Nam K, Roh J, Lee H, et al.
Am J Cardiovasc Drugs
. 2024 Nov;
25(2):267-276.
PMID: 39487337
Background And Objectives: Cilostazol improves ischemic symptoms and prevents recurrence following cerebral infarction, and rosuvastatin reduces cholesterol levels. However, no reports exist on the pharmacokinetic interactions between these two drugs...
3.
Park Y, Kim J, Kim S, Lee J, Hong J, Jung J, et al.
Clin Transl Sci
. 2024 Oct;
17(10):e70037.
PMID: 39351819
CT-P13, a biosimilar of infliximab, is used to treat inflammatory diseases that arise from immune system complications, resulting in excessive and persistent inflammation. The subcutaneous (SC) formulation of CT-P13 overcomes...
4.
Lim H, Kim J, Hong J, Jung J, Sunwoo J
Clin Pharmacol Drug Dev
. 2024 Sep;
13(12):1345-1354.
PMID: 39330938
A fixed-dose combination (FDC) of ezetimibe, atorvastatin, and amlodipine has been developed to improve medication adherence among patients with cardiovascular diseases. In a randomized, open-label, multiple-dose, fixed-sequence study involving 34...
5.
Kim J, Song J, Kim M, Hong J, Sunwoo J, Jung J
Adv Ther
. 2024 May;
41(7):2808-2825.
PMID: 38771476
Introduction: Fixed-dose combinations (FDCs) of angiotensin II receptor blockers, calcium channel blockers, and statins are conventional therapeutic interventions prescribed for cardiovascular diseases. This study aimed at drawing a comparison between...
6.
Kim J, Hong J, Jung J, Jung W, Nam K, Roh J, et al.
Clin Pharmacol Drug Dev
. 2024 Mar;
13(8):842-851.
PMID: 38469999
The combined cilostazol and rosuvastatin therapy is frequently used for coronary artery disease treatment. This open-label, 3 × 3 crossover clinical trial evaluated the pharmacokinetics and safety of a fixed-dose...
7.
Jeong W, Sunwoo J, You Y, Park J, Min J, In Y, et al.
Sci Rep
. 2024 Feb;
14(1):4574.
PMID: 38403792
Administration of sedatives for post-resuscitation care can complicate the determination of the optimal timing to avoid inappropriate, pessimistic prognostications. This prospective study aimed to investigate the distribution and elimination kinetics...
8.
Kim A, Hong J, Shin W, Yoo H, Jung J, Reginster J, et al.
Expert Opin Biol Ther
. 2024 Feb;
24(7):655-663.
PMID: 38349618
Background: This study's objective was to demonstrate pharmacokinetic (PK) similarity and safety of denosumab biosimilar, CT‑P41, and United States-licensed reference denosumab (US-denosumab) in healthy male Asian adults, considering also pharmacodynamic...
9.
Hong J, Jin E, Sung J, Chang I, Kang H, Lee S
Medicine (Baltimore)
. 2023 Oct;
102(43):e35103.
PMID: 37904476
Aberrant regulation of the long non-coding RNA SRY-box transcription factor 2 overlapping transcript (SOX2OT) has been reported in various diseases including gastric cancer (GC). However, an association between the well-studied...
10.
Kim G, Moon H, Kim T, Yun S, Yun H, Hong J, et al.
Pharmaceutics
. 2023 Sep;
15(9).
PMID: 37765325
Camostat mesylate is expected to be promising as a treatment option for COVID-19, in addition to other indications for which it is currently used. Furthermore, in vitro experiments have confirmed...